Clinical trials
catalyst calendar across sponsors →Studies where SEPN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 12 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, Balyasny Asset Management L.P., TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., +7 more) · FINRA short interest 14.2 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 8 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult ParticipantsNCT07433179Frequency of treatment emergent adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Recruiting | Drug: SEP-479 · Other: Placebo | Healthy Volunteers | 150 | Feb 2027 | ≤ 193 d | 2026-04-22 |
| A Study to Evaluate Single and Multiple Doses of SEP-631 in Healthy Adult VolunteersNCT07069036Frequency of treatment emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: SEP-631 · Other: Placebo | Healthy Volunteers | 120 | 2025-12-18actual | — | 2026-04-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19